Christopher Kevil

Sulfagenix, Inc. operates as a biotechnology company. It offers SG1002, a natural-occurring molecule and hydrogen sulfide for, which deficits have been shown to exist in various serious diseases, including cardiovascular disease, type II diabetes, cancer, hypertension, Alzheimer’s disease, asthma, and wound healing. The company was founded by David Lefer and Gabriel Gojon, Sr. in 2011 and is headquartered in Chesterland, OH.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA.

Alteris Therapeutics, Inc. develops therapeutic cancer vaccine products. It engages in engages in the discovery and development of therapeutics and vaccines based on alternative gene splice forms for the treatment of cancer. The company was founded by Donald M. O’Rourke and Albert Wong in 2002 and is headquartered in Philadelphia, PA.

Part of Patrys Ltd., Acceptys, Inc. develops natural antibody technologies for infectious disease applications. The company is based in Sparta, NJ. Acceptys was acquired by Patrys Ltd. on December 03, 2008 for $2 million.

NeuroTherapia, Inc. discovers and develops new therapies for diseases with an underlying component of neuroinflammation. The company was founded by Mohamed Naguib Attala and Joseph F. Foss in 2015 and is headquartered in Cleveland, OH.

Merand Pharmaceuticals, Inc. engages in the provision of therapeutic products. It is developing a novel microRNA therapeutic (MicroRNA93 or miR-93) to treat patients suffering from Peripheral Arterial Disease (PAD). The company was founded in 2018 and is headquartered in Charlottesville, VA.